Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody‐dependent cytotoxicity and improves overall survival against CD20+ rituximab‐sensitive/‐resistant Burkitt lymphoma (BL) and precursor B‐acute lymphoblastic leukaemia (pre‐B‐ALL): potential targeted therapy in patients with poor risk CD20+ BL and pre‐B‐ALL

Awasthi, Aradhana ; Ayello, Janet ; Van de Ven, Carmella ; Elmacken, Mona ; Sabulski, Anthony ; Barth, Matthew J. ; Czuczman, Myron S. ; Islam, Humayun ; Klein, Christian ; Cairo, Mitchell S.

British journal of haematology, 2015-12, Vol.171 (5), p.763-775 [Periódico revisado por pares]

England

Texto completo disponível